Literature DB >> 12271413

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.

Andreas Buck1, Holger Schirrmeister, Thorsten Kühn, Changxian Shen, Thomas Kalker, Jörg Kotzerke, Anja Dankerl, Gerhard Glatting, Sven Reske, Torsten Mattfeldt.   

Abstract

The aim of this study was to evaluate the possible correlation between preoperative FDG-PET results in human breast cancer and the prognostic markers Ki-67, c- erb B2, p53, oestrogen/progesterone receptor status, axillary lymph node status, tumour size and tumour grading. Seventy-five female patients with breast cancer were included in this prospective study. Patient selection was independent of tumour size and the suspected clinical stage of disease. A high-resolution full-ring scanner (Siemens ECAT HR+) was used for PET imaging. The FDG uptake of breast tumours was calculated as the tumour to background ratio (TBR). In resected cancer tissue specimens, the proliferative fraction was evaluated by Ki-67 immunostaining. Additionally, immunostaining of the prognostic markers c-erb B2, p53, and progesterone and oestrogen receptors was performed. Haematoxylin and eosin-stained sections were used for tumour grading. Correlations between FDG uptake and prognostic markers were assumed to be significant at P<0.05 using the Mann-Whitney U test. In ductal breast cancer, mean TBR was 17.3 (median 7.7, range 1.6-122.7), while in lobular cancer it was 6.5 (median 3.7, range 1.4-22.7). Mean proliferative fraction (% Ki-67 positive tumour cells) was 15%+/-13.8% (median 10%, range 0%-60%). Twenty-three carcinomas showed <5% Ki-67 positive tumour cells. Statistical analysis indicated a positive correlation between FDG uptake and proliferative index in ductal breast cancer ( P<0.0001, r=0.63). By contrast, there was no correlation between FDG uptake and c- erb B2 ( P=0.79), p53 ( P=0.92), tumour grading ( P=0.09), oestrogen receptor status ( P=0.41), progesterone receptor status ( P=0.34), axillary lymph node status ( P=0.90) and tumour size ( P=0.3). It is concluded that FDG uptake is significantly higher in ductal breast cancer than in lobular cancer ( P<0.05). FDG uptake correlates with proliferative activity assessed by Ki-67 immunostaining ( P<0.05). A significant correlation with the other prognostic markers, however, could not be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271413     DOI: 10.1007/s00259-002-0880-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  84 in total

1.  Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Junichi Kodama; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-10       Impact factor: 9.236

Review 2.  PET/CT and breast cancer.

Authors:  Barbara Zangheri; Cristina Messa; Maria Picchio; Luigi Gianolli; Claudio Landoni; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

3.  Breast scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

4.  Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.

Authors:  Nina Mortazavi-Jehanno; Anne-Laure Giraudet; Laurence Champion; Florence Lerebours; Elise Le Stanc; Veronique Edeline; Olivier Madar; Dominique Bellet; Alain Paul Pecking; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

5.  [Functional and molecular imaging of breast tumors].

Authors:  K Pinker; P Brader; G Karanikas; K El-Rabadi; W Bogner; S Gruber; M Reisegger; S Trattnig; T H Helbich
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

6.  Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer.

Authors:  Laura Evangelista; Zora Baretta; Lorenzo Vinante; Anna Rita Cervino; Michele Gregianin; Cristina Ghiotto; Giorgio Saladini; Guido Sotti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-30       Impact factor: 9.236

7.  [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.

Authors:  Alina Berriolo-Riedinger; Claude Touzery; Jean-Marc Riedinger; Michel Toubeau; Bruno Coudert; Laurent Arnould; Christophe Boichot; Alexandre Cochet; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-20       Impact factor: 9.236

8.  18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.

Authors:  Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Nariya Cho; Jung Min Chang; Min Sun Bae; Won Hwa Kim; Su Hyun Lee; Mi Young Kim; Jin You Kim; Mirinae Seo; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

9.  Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.

Authors:  M G Caprio; A Cangiano; M Imbriaco; F Soscia; G Di Martino; A Farina; G Avitabile; L Pace; P Forestieri; M Salvatore
Journal:  Radiol Med       Date:  2009-12-16       Impact factor: 3.469

10.  Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography.

Authors:  T Kato; J Shinoda; N Nakayama; K Miwa; A Okumura; H Yano; S Yoshimura; T Maruyama; Y Muragaki; T Iwama
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-03       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.